Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3314537 | 1.00 | TDP1 (0.41) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL3314570 | 0.99 | TDP1 (0.42) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL3314576 | 0.99 | TDP1 (0.42) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL3314579 | 0.95 | TDP1 (0.38) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL3314379 | 0.94 | TDP1 (0.38) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL3318441 | 0.94 | ATM (0.37) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL3318444 | 0.94 | ATM (0.37) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL13397997 | 0.89 | SCN1A (0.35) | SIGMAR1SCN1ASCN2ASCN3AMEN1 | |
| SCHEMBL3315899 | 0.88 | SIGMAR1 (0.44) | TDP1SIGMAR1SCN1ASCN2ASCN3A | |
| SCHEMBL3318083 | 0.88 | FKBP1A (0.37) | TDP1FKBP1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-2129659-B1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | C9, C1R, CBR3 | TDP1 4511/4885SIGMAR1 108/4885SCN1A 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.